Dupilumab Demonstrates Safety, Efficacy in Pediatric AD Patients Ages 6 Months to 5 Years
August 31st 2021Regeneron Pharmaceuticals, Inc. and Sanofi announced safety and efficacy results from the LIBERTY AD trial investigating dupilumab in pediatric patients ages 6 months to 5 years with atopic dermatitis.